---
title: "July FDA Peptide Meeting Update"
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/42306194.md"
description: "Yesterday's document was just a preliminary opinion. The PCAC committee will provide recommendations to the FDA at the meeting, and the FDA will make a final decision after considering the PCAC's input. The FDA just added 8 new panel members, most of whom are affiliated with companies that promote or prescribe peptide products. Therefore, the committee has now effectively been "stacked" to be more inclined to give favorable recommendations for peptides. PCAC is purely advisory. Its vote is not binding. The FDA still retains the final decision-making authority. Theoretically..."
datetime: "2026-06-30T05:23:37.000Z"
locales:
  - [en](https://longbridge.com/en/topics/42306194.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/42306194.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/42306194.md)
author: "[ST欧阳昆汀(被困Hims版)](https://longbridge.com/en/profiles/4868421.md)"
---

# July FDA Peptide Meeting Update

**Yesterday's document was just a preliminary opinion.** The PCAC committee will provide recommendations to the FDA at the meeting, and the FDA will make a final decision after considering PCAC's input.

**The FDA just added 8 new panel members, most of whom are associated with companies that promote or prescribe peptide products.** Therefore, the committee has now effectively been "stacked" to be more inclined to give favorable recommendations for peptides.

PCAC is purely **advisory**. Its vote is **non-binding**. The FDA still retains the final decision-making authority. Theoretically, if the expert panel votes "**YES PEPTIDES**", the FDA can still refuse to add these peptides.

However—the "FDA" is not an entity with views independent of its leadership. It reports to HHS (the U.S. Department of Health and Human Services), and HHS = RFK. So the real fight isn't "FDA vs. PCAC." It's more likely a battle between the **FDA career staff** and the **FDA / HHS / RFK political leadership**.

If RFK + HHS + a stacked panel all want approval, and only the career staff's document says "no"—then the likelihood of approval is high. The staff document here is the only **completely non-binding** input, and everyone above it in the decision chain wants the opposite outcome. The career staff will lose this fight.

This doesn't mean peptide approval is guaranteed. But among all the obstacles, today's document is the easiest one to overturn.$Hims & Hers Health(HIMS.US)$HIMS 2X Long ETF(HIMZ.US)

### Related Stocks

- [HIMZ.US](https://longbridge.com/en/quote/HIMZ.US.md)
- [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md)

## Comments (3)

- **OrangeToast · 2026-06-30T06:18:11.000Z**: Waiting for a wave of results, getting ready to rebalance the portfolio
  - **ST欧阳昆汀(被困Hims版)** (2026-06-30T06:25:50.000Z): How much more to break even?
  - **OrangeToast** (2026-06-30T14:20:27.000Z): Not much left, 10%. Can't ignore market fluctuations and just "value invest" anymore. Need to be more diligent.